MEN 2B (multiple endocrine neoplasia type 2B) is an autosomal dominant cancer syndrome caused by an oncogenic form of the receptor tyrosine kinase REarranged during transfection (RET). The MEN 2B syndrome is associated with an abnormal autophosphorylation of the mutated receptor even without ligand-stimulation. Here, we characterize the activation of a RET MEN 2B variant carrying the point mutation Met918Thr, and show that the 150 kDa precursor of RET MEN 2B becomes phosphorylated already during synthesis in the endoplasmic reticulum (ER). At least three different tyrosine residues (Tyr905, Tyr1062, Tyr1096) of the RET MEN 2B precursor are phosphorylated before the oncogenic receptor reaches the cell surface. We also demonstrate that the precursor of RET MEN 2B interacts with both growth factor receptorbound protein and Src homology 2 domain-containing already in the ER, and that this interaction is dependent on the kinase activity of RET. With the aid of two RET mutants (RET MEN 2B/S32L and RET MEN 2B/F393L
MEN 2B (multiple endocrine neoplasia type 2B) is an autosomal dominant cancer syndrome caused by an oncogenic form of the receptor tyrosine kinase REarranged during transfection (RET). The MEN 2B syndrome is associated with an abnormal autophosphorylation of the mutated receptor even without ligand-stimulation. Here, we characterize the activation of a RET MEN 2B variant carrying the point mutation Met918Thr, and show that the 150 kDa precursor of RET MEN 2B becomes phosphorylated already during synthesis in the endoplasmic reticulum (ER). At least three different tyrosine residues (Tyr905, Tyr1062, Tyr1096) of the RET MEN 2B precursor are phosphorylated before the oncogenic receptor reaches the cell surface. We also demonstrate that the precursor of RET MEN 2B interacts with both growth factor receptorbound protein and Src homology 2 domain-containing already in the ER, and that this interaction is dependent on the kinase activity of RET. With the aid of two RET mutants (RET MEN 2B/S32L and RET
MEN 2B/F393L
), which accumulate in the ER, we show that the oncogenic precursor of the receptor has the capacity to activate AKT, extracellular signal-regulated kinase and signal transducer and activator of transcription 3 from the ER. Taken together, our data demonstrate that the oncogenic precursor of RET MEN 2B is phosphorylated, interacts with adapter proteins and induces downstream signalling from the ER. Oncogene (2007) 26, 7909-7915; doi:10.1038/sj.onc.1210591; published online 18 June 2007 Keywords: RET; MEN 2B; precursor; downstream signalling; endoplasmic reticulum RE arranged during transfection (RET) is a transmembrane receptor tyrosine kinase, which in the presence of a glycosyl phosphatidylinositol-anchored co-receptor GDNF family receptor (GFRa) can be activated by glial cell line-derived neurotrophic factor (GDNF) family ligands (GFLs). There are four different GFLs (GDNF, neurturin, artemin and persephin), which bind to the coreceptors GFRa1-4, respectively. As RET is the signal transducer of four different ligand/co-receptor complexes, it has important physiological functions in different tissues. In spite of its broad expression pattern and vitally important functions during development (Airaksinen and Saarma, 2002) , the oncogenic mutant forms of RET cause quite limited clinical symptoms -activating mutations in RET are only responsible for hereditary endocrine cancer syndromes (Kodama et al., 2005) . This paradox has not yet been explained, and is likely due to some still uncharacterized activation or inactivation mechanisms of RET.
Based on the clinical symptoms, the multiple endocrine neoplasia type 2 (MEN 2) is divided into three groups: MEN 2A, MEN 2B and familiar medullary thyroid carcinoma (FMTC). In MEN 2A, the disease has been linked to point mutations, which are mostly located to cysteine residues in the extracellular cysteine-rich domain of RET. These point mutations introduce abnormal intermolecular cysteine bridges, and cause an autoactivation of RET MEN 2A by dimerization. In the case of MEN 2B, the point mutations are located in the intracellular domain of RET where they cause an autoactivation of RET MEN 2B monomers. In FMTC patients, point mutations have been found both in the extracellular and the intracellular domain of RET (Hansford and Mulligan, 2000) . Several attempts have been made to develop methods that would inhibit the activity of oncogenic RET. These methods are based on competitive inhibition using the soluble RET extracellular domain (Cerchia et al., 2003) , blocking with inhibitory extracellular antibodies, chemical inhibition or gene transfer (reviewed by Kodama et al., 2005) . Part of these inhibitory approaches affect RET from the extracellular side, whereas part of them affect RET from the intracellular side. Therefore, knowledge on which cellular membranes oncogenic RET is activated is needed.
So far it has remained unclear on what stage of their biogenesis the oncogenic RET receptors become activated. On one hand, secretory proteins are folded already in the endoplasmic reticulum (ER), but on the other hand, one should consider the possibility that the full activity of RET could depend on some specific component that is present only at the plasma membrane. The synthesis of RET has been well documented, and RET has been shown to pass the ER as a partially glycosylated 150 kDa precursor, which reaches the cell surface as a mature 170 kDa receptor (van Weering et al., 1998) . However, very contradictory results have been reported on the activity of RET 150 kDa precursor, and it has remained unclear whether the precursor is active or inactive (Miyazaki et al., 1993; Asai et al., 1995; Santoro et al., 1995; Carlomagno et al., 1996 Carlomagno et al., , 1998 Bongarzone et al., 1998; Freˆche et al., 2005) . One reason for this is that mutations that affect the maturation and transport of RET to the cell surface also significantly decrease the kinase activity of both the precursor and mature form of the receptor (Asai et al., 1995; Chappuis-Flament et al., 1998; Cosma et al., 1998) . Therefore, it has been technically difficult to determine whether the intracellular RET MEN 2 precursors have biological activity or not. Here, we used a new approach to study whether RET MEN 2B precursors are active before reaching the cell surface. Figure 1 RET MEN 2B is phosphorylated during synthesis in the ER. The rat GFRa1 construct used in this work (accession number AJ002072) was tagged with the FLAG epitope and has previously been characterized (Virtanen et al., 2005) . The human RET constructs (long isoform, accession number NM_000323) were from Marc Billaud (Pelet et al., 1998) , and were subcloned into pCR3.1. All point mutations were introduced by inverse PCR mutagenesis, and all DNA constructs were sequenced throughout. PC6-3 cells (a subclone of PC12 cells) do not express GFRa1 and have very low levels of endogenous RET (Virtanen et al., 2005) . All transfections were carried out using Lipofectamine TM 2000 (Invitrogen, Carlabad, CA, USA) unless otherwise indicated. (a) PC6-3 cells were transfected with GFRa1 alone or co-transfected with GFRa1/RET WT (24 h) and the cells were stimulated with GDNF (PeproTech Ltd, Rocky Hill, NJ, USA) at 100 ng/ml for 10 min. Cells were lysed, RET was immunoprecipitated (IP) from the post-nuclear supernatant and the samples were analysed by western blotting (WB) with antibodies to phosphotyrosine (P-Tyr), (4G10, Upstate Biotechnology, Lake Placid, NY, USA). The membrane was stripped and reprobed with antibodies to RET (goat, C-20, Santa Cruz Biotechnology, Santa Cruz, CA, USA). (b) PC6-3 cells were transiently co-transfected with GFRa1/RET WT or GFRa´1/RET MEN 2B . After the indicated transfection time (2-8 h), the cells were stimulated with 100 ng/ml of GDNF for 10 min, lysed and analysed as in (a). WT or GFRa1/RET MEN 2B . The cells were stimulated with 100 ng/ml of GDNF for 10 min and lysed. RET was immunoprecipitated (IP) from the extracts and each sample was divided into three parallel samples for western blot analysis (WB) with antibodies to phosphorylated tyrosine residues of RET (PY905, PY1062 and PY1096). The filters were stripped and reprobed with antibodies to phosphotyrosine and RET. ER, endoplasmic reticullum; GDNF, glial cell line-derived neurotrophic factor.
It is well known that a long-term overexpression of RET leads to the auto-activation of RET, so that GDNF can elicit only a minor additional increase in the level of RET-phosphorylation (Figure 1a) . Therefore, we used a short transient transfection to express GFRa1/RET WT or GFRa1/RET MEN 2B
. By taking early time course samples after the transfection, we could follow the synthesis and activation of RET WT and RET MEN 2B (Figure 1b) . The RET MEN 2B mutant that was used in this work harbours the point mutation M918T. The majority of MEN 2B patients have a mutation in this codon (Mulligan and Ponder, 1995) . Our results showed that RET MEN 2B becomes phosphorylated independently of the GDNF stimulation already as an intracellular 150 kDa precursor.
To confirm that the 150 kDa form of RET in the PC6-3 cells corresponds to a precursor form which is located in the ER, we transiently transfected these cells in the presence of brefeldin A, which disrupts the function of both the intermediate compartment and the Golgi complex and traps secretory proteins in the ER (Figure 1c) . The results verified that the 150 kDa precursor of RET MEN 2B is located in the ER and is phosphorylated. In this assay, we also included a kinase-dead form of the oncogenic MEN 2A (RET   MEN 2A/E921K ), which harbours the double mutation C634R/E921K (Pelet et al., 1998) . The lack of phosphorylation of RET in this negative control showed that the activation of the precursor of RET is dependent on its own kinase domain. In addition, as GFRa1 was excluded from this assay, our results show that the activity of the precursor does not require the presence of GFRa1.
Previously, the tyrosine residues 905, 1015, 1062 and 1096 of the mature, 170 kDa form of RET have been Figure 2 RET MEN 2B recruits the adapter proteins SHC and GRB to the ER. (a) PC6-3 cells were transiently co-transfected (6 h) with GFRa1/RET WT or GFRa1/RET MEN 2B . After stimulation with GDNF (10 min, 100 ng/ml), the samples were lysed. Each sample was divided into two parallel parts before the immunoprecipitation. From one part SHC-associated proteins were co-immunoprecipitated (IP) with antibodies to SHC (catalogue/610081, Transduction Laboratories, Lexington, KY, USA). The SHC-immunoprecipitated samples were analysed by western blotting (WB) with antibodies to RET. The second part of the sample was used as a control to elucidate if the degree of association between SHC and RET is related to the expression and phosphorylation level of the transiently expressed different forms of RET. This part of the sample was analysed as in shown to become phosphorylated upon GDNFstimulation at the plasma membrane (Tsui-Pierchala et al., 2002) . Antibodies that recognize the phosphorylated tyrosine residues 905, 1015, 1062 and 1096 have been characterized with the aid of RET constructs harbouring specific point mutations (Tsui-Pierchala et al., 2002) . Here, we used these antibodies to study if the same tyrosines also are phosphorylated in the intracellular RET MEN 2B precursor (Figure 1d ). In our hands, these antibodies recognized only high levels of phosphorylated RET, and it was therefore necessary to overexpress RET in this experiment. A drawback of this set up is that the overexpression of the receptors leads to an auto-activation of even the RET WT form. In spite of the high background our results confirm that GDNF indeed induces the phosphorylation of tyrosines 905, 1062 and 1096 on the mature form of RET WT . The antibodies to phosphorylated tyrosine 1015 gave a weak signal, and we could not detect any GDNF-induced phosphorylation with these antibodies (data not shown). The antibodies to phosphotyrosines 905, 1062 and 1096 recognized a strong phosphorylation of the 150 kDa precursor form of RET, and showed that the oncogenic precursor of RET MEN 2B is much more phosphorylated at these tyrosine residues than the precursor of RET WT ( Figure 1d ).
The phosphorylation of tyrosine residue 1062, and its function as a docking site for the Src homology 2 domain-containing (SHC) adapter have been reported to be important for the pathogenic function of RET MEN 2B (Asai et al., 1996; Salvatore et al., 2001 ). Therefore, we next set out to study if the precursor of RET MEN 2B has the capacity to recruit the adapter protein SHC to the surface of ER. In order to obtain more reliable results, we performed the assay in two different ways. First, we immunoprecipitated SHC and assayed if the 150 kDa precursor form of RET was co-immunoprecipitated. This assay was carried out in the absence of brefeldin A and the precursor nature of RET was identified based on its molecular weight. The results showed that although the expression level of RET MEN 2B was lower than that of RET WT , it was more strongly phosphorylated and its 150 kDa precursor recruited more SHC than the precursors of RET WT (Figure 2a) . using LF. The lysate was divided into two parts. One part was used as a total lysate for western blot analysis of phospho-AKT (catalogue/9271, Cell Signaling Technology, USA). This membrane was then stripped and reprobed with antibodies to AKT (catalogue/9272, Cell Signaling Technology, Danvers, MA, USA). The other part was used to verify the expression of RET in the samples. RET was immunoprecipitated and the precipitate was analysed by western blot analysis with antibodies to phosphotyrosine residues. (b) PC6-3 cells were untreated, treated with magnetic beads or transiently transfected (8 h) with RET WT or RET MEN 2B using magnetic beads (MATra-A reagent, IBA GmbH, Germany). The transfection procedure was modified from the manufacturer's instructions. To increase the transfection and protect the PC6-3 cells, we shortly exposed the cells to high concentrations of beads. The assay was performed both in the absence and presence of brefeldin A. The lysate was analysed as in (a). The results from two independent experiments were similar. The lower part of the panel shows the quantification of the western blot results, the y axis shows the optical density/mm 2 after subtraction of the background (od-Bkg/mm 2 ).
RET
MEN 2B is active in the endoplasmic reticulum P Runeberg-Roos et al Second, we transiently expressed RET in the presence of brefeldin A, subsequently immunoprecipitated the ER-arrested receptor and tested if it was associated with SHC. The results of this second assay also showed that there is an association between SHC and the intracellular 150 kDa precursor of RET MEN 2B (Figure 2b ). Since the latter assay was carried out in the absence of GFRa1, it also showed that the association between the precursor of RET MEN 2B and SHC is not dependent on the presence of GFRa1.
To further characterize the binding of adapter proteins to the precursor of RET MEN 2B , we generated and used three previously characterized mutant forms of RET. The first (RET E921K ) is a kinase-dead mutant of RET WT , which we used as a negative control in the assays (Pelet et al., 1998) cannot be detected, and that its 150 kDa precursor is located inside the cell (Carlomagno et al., 1996) . In the case of RET MEN 2B/F393L
, the secretion deficiency is less severe and low amounts of the mature receptor are detectable (Carlomagno et al., 1996) . It is well established that the 150 kDa form of RET is a partially glycosylated precursor, which is located in the ER. This has been shown with the aid of several methods, such as treatment of cells with tunicamycin or brefeldin A (Takahashi et al., 1991; van Weering et al., 1998) , digestion of isolated RET proteins with Endo H (Cosma et al., 1998) , pulse chase experiments (van Weering et al., 1998) and biotinylation of cell surface proteins (Carlomagno et al., 1996; van Weering et al., 1998) . Based on our data showing that the precursor of RET MEN 2B is both phosphorylated on key tyrosine residues and associated with at least two adapter proteins (SHC and GRB2), we wanted to see if this activation also evoked further downstream signalling events. A strong phosphorylation of the tyrosine residue 1062 in RET is correlating with an enhanced activation of AKT (Salvatore et al., 2001) , and we therefore wanted to know if the RET MEN 2B precursor also could activate AKT. As one mean to lock RET into the ER, we used a short transient expression of RET in the presence of brefeldin A, but we were cautious about the possibility that our transfection method (based on cationic lipids) could interfere with the results. As the transfection reagent indeed induced a strong phosphorylation of AKT (Figure 3a) , we changed to another transfection method, the magnet assisted transfection system. In addition, we took into account that brefeldin A, possibly through ER-stress, would affect the results. Therefore, we assayed the activation of AKT, both in the presence and absence of brefeldin A. Each lysate was divided into two parts. One part was used for the analysis of AKT-activation and the other part was used to verify the expression of RET in the samples. Our results show that the transfection procedure with the magnetic beads does not activate AKT (Figure 3b) . These results also show that the presence of brefeldin A reduces the level of phosphorylated AKT in all samples, including the untreated control. In spite of this overall reduced level of AKT activity, our results showed that the expression of the intracellular precursors of both RET WT and RET MEN 2B in the ER leads to an increased phosphorylation of AKT.
To further characterize the downstream signalling capacity of the precursor of RET MEN 2B
, we used the , and also compared it to another mutant RET MEN 2B/F393L (both described above). RET MEN 2B/S32L is not secreted to the cell surface and it therefore enabled us to study the RET-dependent downstream signalling in the absence of brefeldin A. With the aid of RET MEN 2B/S32L
, we were able to prolong the transfection time to 28 h and detect a more robust induction of signalling. Lipofectamine 2000 was withdrawn from cells after the first 3 h and did therefore not interfere with the results. RET has been shown to activate many different signalling pathways, which are dependent on different tyrosine residues in the RET intracellular domain. The activation of AKT and extracellular signal-regulated kinase depends on the phosphorylation of tyrosines 1062 and 1096 in RET, while the activation of signal transducer and activator of transcription 3 (STAT3) may depend on tyrosines 752 and 928 (Kodama et al., 2005) . Here, we show that the expression of the 150 kDa precursor form of RET MEN 2B/S32L clearly induces the phosphorylation of not only AKT but also ERK and STAT3 (Figure 4 ).
In conclusion, we have used several different methods to show that the precursor of RET MEN 2B has the capacity to induce downstream signalling in the ER. Although only a very weak downstream signalling could previously be detected from the RET MEN 2B precursor in the ER, our results are fully in line with the well-documented signalling capacity of RET PTC , which is another oncogenic form of RET. Patients with this type of cancer have a chromosomal re-arrangement in which the intracellular kinase domain of RET in its N-terminus is fused to a soluble protein, which spontaneously forms cytoplasmic dimers and thereby induces an activation of the RET kinase domain (Kodama et al., 2005) . RET PTC indeed activates STAT3, ERK and AKT (Hwang et al., 2003; Knauf et al., 2003; Miyagi et al., 2004) , although it is a cytoplasmic protein that does not reach the cell surface.
